切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2020, Vol. 14 ›› Issue (03) : 150 -155. doi: 10.3877/cma.j.issn.1674-0807.2020.03.005

所属专题: 文献

论著

氟维司群单药对激素受体阳性复发、转移性乳腺癌患者疗效的单中心分析
李晶晶1, 王小磊1, 任鹏飞1, 杨震1, 陈婵娟1, 琚倩1, 李烦繁1,()   
  1. 1. 230601 合肥,安徽医科大学第二附属医院肿瘤科
  • 收稿日期:2019-12-30 出版日期:2020-06-01
  • 通信作者: 李烦繁
  • 基金资助:
    安徽高校自然科学基金资助项目(KJ2019A0258)

Efficacy of fulvestrant monotherapy for hormonal receptor-positive recurrent or metastatic breast cancer: a single center analysis

Jingjing Li1, Xiaolei Wang1, Pengfei Ren1, Zhen Yang1, Chanjuan Chen1, Qian Ju1, Fanfan Li1,()   

  1. 1. Department of Oncology, Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
  • Received:2019-12-30 Published:2020-06-01
  • Corresponding author: Fanfan Li
  • About author:
    Corresponding author: Li Fanfan, Email:
引用本文:

李晶晶, 王小磊, 任鹏飞, 杨震, 陈婵娟, 琚倩, 李烦繁. 氟维司群单药对激素受体阳性复发、转移性乳腺癌患者疗效的单中心分析[J/OL]. 中华乳腺病杂志(电子版), 2020, 14(03): 150-155.

Jingjing Li, Xiaolei Wang, Pengfei Ren, Zhen Yang, Chanjuan Chen, Qian Ju, Fanfan Li. Efficacy of fulvestrant monotherapy for hormonal receptor-positive recurrent or metastatic breast cancer: a single center analysis[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2020, 14(03): 150-155.

目的

回顾性分析氟维司群单药治疗激素受体阳性复发、转移性乳腺癌患者的疗效及其与临床病理特征的相关性。

方法

收集2017年8月至2019年8月在安徽医科大学第二附属医院治疗的激素受体阳性乳腺癌患者的临床资料。选取既往接受过辅助内分泌治疗,且在复发、转移后接受过氟维司群单药治疗的患者52例,采用Kaplan-Meier法计算氟维司群单药治疗的无进展生存期(PFS),采用log-rank法分析各临床病理因素对PFS的影响。将单因素分析差异有统计学意义的变量纳入多因素Cox回归模型进行分析,得到影响氟维司群疗效的独立危险因素。

结果

52例患者的中位随访时间为15.2个月(范围:10.9~19.0个月),中位PFS为8.3个月(95%CI:5.5~10.4个月)。30例早复发(辅助内分泌治疗过程中或辅助内分泌治疗结束后≤1年复发或转移)与22例晚复发(完成辅助内分泌治疗结束后>1年复发或转移)患者的中位PFS分别为6.3个月(95%CI:4.5~7.5个月)和13.4个月(95%CI:7.7~18.3个月),差异有统计学意义(χ2=9.280,P=0.002)。21例有肝转移与31例无肝转移患者的中位PFS分别为5.0个月(95%CI:3.9~6.1个月)和10.3个月(95%CI:6.4~13.6个月),差异有统计学意义(χ2=7.544,P=0.006)。25例复发或转移后接受化疗与27例未接受化疗患者的中位PFS分别为5.2个月(95%CI:3.7~6.3个月)和11.3个月(95%CI:8.5~13.5个月),差异有统计学意义(χ2=7.305,P=0.007)。45例PR阳性与7例PR阴性患者的中位PFS分别为9.0个月(95%CI:6.3~11.7个月)和4.2个月(95%CI:2.8~5.1个月),差异有统计学意义(χ2=6.869,P=0.009)。Cox多因素分析显示复发时间短和复发、转移后接受化疗是影响氟维司群疗效的独立危险因素(HR=3.474,95%CI:1.534~7.866, P=0.003;HR =2.822, 95%CI:1.349~5.9,P=0.006)。

结论

既往接受辅助内分泌治疗的激素受体阳性复发、转移性乳腺癌患者接受氟维司群单药治疗时,复发晚、既往未接受化疗和无肝转移的患者获益更大。

Objective

To retrospectively analyze the efficacy of fulvestrant monotherapy for hormonal receptor (HR)-positive recurrent or metastatic breast cancer and its relationship with clinicopathological features.

Methods

The clinical data of HR-positive breast cancer patients in the Second Affiliated Hospital of Anhui Medical University from August 2017 to August 2019 were collected. Among them, 52 patients who had history of adjuvant endocrine therapy and underwent fulvestrant monotherapy after recurrence and metastasis were enrolled into this study. Kaplan-Meier method was used to calculate the progression-free survival (PFS) of patients after fulvestrant monotherapy and log-rank test was used to analyze the effect of clinicopathological features on PFS. The significant factors in univariate analysis were included in the multivariate Cox regression model to screen out independent risk factors.

Results

All patients were followed up for 10.9-19.0 months (median 15.2 months). The median PFS of 52 patients was 8.3 months (95%CI: 5.5-10.4 months). The median PFS was 6.3 months (95%CI: 4.5-7.5 months) in 30 patients with early recurrence(disease recurrence during adjuvant endocrine therapy or within 12 months after adjuvant endocrine therapy)and 13.4 months (95%CI: 7.7-18.3 months)in 22 patients with late recurrence (disease recurrence over 12 months after adjuvant endocrine therapy), indicating a significant difference (χ2=9.280, P=0.002). The median PFS was 5.0 months (95%CI: 3.9-6.1 months) in 21 patients with liver metastasis and 10.3 months (95%CI: 6.4-13.6 months) in 31 patients without liver metastasis, indicating a significant difference (χ2=7.544, P=0.006). The median PFS was 5.2 months (95%CI: 3.7-6.3 months) in 25 patients with chemotherapy after recurrence or metastasis and 11.3 months (95%CI: 8.5-13.5 months) in 27 patients without chemotherapy, indicating a significant difference (χ2=7.305, P=0.007). The median PFS was 9.0 months (95%CI: 6.3-11.7 months) in 45 PR-positive patients and 4.2 months (95%CI: 2.8-5.1 months) in 7 PR-negative patients, indicating a significant difference (χ2=6.869, P=0.009). Cox multivariate analysis showed that early recurrence (HR=3.474, 95%CI: 1.534-7.866, P=0.003) and chemotherapy after recurrence or metastasis (HR=2.822, 95%CI: 1.349-5.9, P=0.006) were independent risk factors for the efficacy of fulvestrant monotherapy.

Conclusion

Fulvestrant is effective for HR-positive recurrent or metastatic breast cancer patients who previously received adjuvant endocrine therapy, especially for those with late recurrence, no chemotherapy or liver metastasis.

表1 52例激素受体阳性复发、转移性乳腺癌患者氟维司群单药治疗后PFS相关因素的Cox回归分析变量赋值情况
表2 52例激素受体阳性复发、转移性乳腺癌患者的临床病理特征
图1 早复发与晚复发的激素受体阳性复发、转移性乳腺癌患者无进展生存曲线比较
图2 有肝转移与无肝转移的激素受体阳性复发、转移性乳腺癌患者无进展生存曲线比较
图3 复发、转移后化疗与未化疗激素受体阳性复发、转移性乳腺癌患者的无进展生存曲线比较
图4 PR阳性与阴性复发、转移性乳腺癌患者的无进展生存曲线比较
表3 52例激素受体阳性复发、转移性乳腺癌患者PFS的单因素分析
表4 52例激素受体阳性复发、转移性乳腺癌患者PFS的Cox比例风险回归分析
[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6): 394-424.
[2]
郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2019,41(4): 315-320.
[3]
Bonotto M, Gerratana L, Di Maio M, et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis[J]. Breast,2017,31(2): 114-120.
[4]
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J]. 中国癌症杂志,2017,27(9): 695-760.
[5]
Robertson J, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, doubleblind, phase 3 trial[J]. Lancet,2016,388(10063): 2997-3005.
[6]
Robertson J, Lindemann J, Garnett S, et al. A good drug made better: the fulvestrant dose-response story[J]. Clin Breast Cancer,2014,14(6): 381-389.
[7]
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol,2010,28(30): 4594-4600.
[8]
Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase Ⅱ FIRST study[J]. J Clin Oncol,2015,33(32): 3781-3787.
[9]
Alluri PG, Speers C, Chinnaiyan AM. Estrogen receptor mutations and their role in breast cancer progression[J]. Breast Cancer Res,2014,16(6): 494.
[10]
Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol,2016,34(25): 2961-2968.
[11]
Graham J, Pitz M, Gordon V, et al. Clinical predictors of benefit from fulvestrant in advanced breast cancer: a meta-analysis of randomized controlled trials[J]. Cancer Treat Rev,2016,45(4): 1-6.
[12]
Araki K, Ishida N, Horii R, et al. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure[J]. Expert Opin Pharmacother,2015,16(17): 2561-2568.
[13]
HE M, Li JJ, Zuo WJ, et al. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant[J]. Cancer Med, 2019,8(14): 6212-6220.
[14]
Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)[J]. Ann Oncol,2014,25(10): 1871-1888.
[15]
Freedman O, Amir E, Dranitsaris G, et al. Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients[J]. Breast Cancer Res Treat,2009,118(2): 377-383.
[16]
Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy[J]. J Clin Oncol,2005,23(30): 7721-7735.
[17]
Liu XY, Ma D, Xu XE, et al. Genomic landscape and endocrine-resistant subgroup in estrogen receptor-positive, progesterone receptor-negative, and HER2-negative breast cancer[J]. Theranostics,2018,8(22): 6386-6399.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
阅读次数
全文


摘要